Pierfranco Conte
Overview
Explore the profile of Pierfranco Conte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
224
Citations
9291
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buja A, Rugge M, Bortolami A, Zorzi M, Rea F, Zanovello A, et al.
Cancers (Basel)
. 2025 Feb;
17(4).
PMID: 40002243
Introduction: This retrospective follow-up study evaluates patient outcomes and treatment costs in two cohorts of incident NSCLC patients recorded in the population-based cancer registry of the Veneto Region in 2017...
2.
Dieci M, Bisagni G, Bartolini S, Schirone A, Cavanna L, Musolino A, et al.
JAMA Oncol
. 2025 Feb;
PMID: 39946142
Importance: For patients with early ERBB2 (formerly HER2)-positive breast cancer, there is a need to identify biomarkers to guide treatment de-escalation. Objective: To evaluate the association of tumor-infiltrating lymphocytes (TILs)...
3.
Elghazaly H, Azim H, Rugo H, Cameron D, Swain S, Curigliano G, et al.
Cancer
. 2024 Jul;
130(19):3251-3271.
PMID: 38985794
Background: The management of early breast cancer (BC) has witnessed an uprise in the use of neoadjuvant therapy and a remarkable reshaping of the systemic therapy postneoadjuvant treatment in the...
4.
Conte P, Guarneri V, DAmico R
J Clin Oncol
. 2024 Jun;
42(25):3062.
PMID: 38913966
No abstract available.
5.
Conte P, Ciruelos E, Curigliano G, De Laurentiis M, Del Mastro L, Gennari A, et al.
Breast
. 2024 May;
76:103742.
PMID: 38772190
Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clinical...
6.
Oliva G, Giustiniani A, Danesin L, Burgio F, Arcara G, Conte P
Oncologist
. 2024 May;
29(7):e848-e863.
PMID: 38723166
Objectives: Cancer-related cognitive impairment (CRCI) refers to a cognitive decline associated with cancer or its treatments. While research into CRCI is expanding, evidence remains scattered due to differences in study...
7.
Conte P, Bisagni G, Piacentini F, Sarti S, Minichillo S, Anselmi E, et al.
J Clin Oncol
. 2023 Sep;
41(32):4976-4981.
PMID: 37748109
JCO We present the final analysis of the phase III noninferiority, randomized ShortHER trial comparing 9 weeks versus 1 year of adjuvant trastuzumab with chemotherapy in patients with human epidermal...
8.
Dieci M, Conte P, Bisagni G, Bartolini S, Frassoldati A, Generali D, et al.
J Natl Cancer Inst
. 2023 Sep;
116(1):69-80.
PMID: 37676829
Background: Even with contemporary treatment strategies, more than 10% of HER2-positive early stage breast cancer patients may experience distant metastasis as first event during follow-up. Tools for predicting unique patterns...
9.
Criscitiello C, Corti C, De Laurentiis M, Bianchini G, Pistilli B, Cinieri S, et al.
Cancer Treat Rev
. 2023 Aug;
120:102618.
PMID: 37639757
Approximately 20% of breast cancers (BCs) overexpress human epidermal growth factor receptor 2 (HER2), a transmembrane glycoprotein with tyrosine kinase activity, encoded by ERBB2 gene. Historically, HER2 overexpression has been...
10.
Cieslik B, Mazurek J, Wrzeciono A, Maistrello L, Szczepanska-Gieracha J, Conte P, et al.
NPJ Digit Med
. 2023 Aug;
6(1):159.
PMID: 37620411
Technological advancements facilitate feedback adaptation in rehabilitation through virtual reality (VR) exergaming, serious gaming, wearables, and telerehabilitation for older adults fall prevention. Although studies have evaluated these technologies, no comparisons...